rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Treating life-threatening bleedings
    sub title: development of recombinant coagulation factor VIIa
  title info:
    title: Development of recombinant coagulation factor VIIa
  name:
    name part: Hedner, U. (Ulla)
    role:
      role term: creator
    role:
      role term: author.
  name:
    name part: ScienceDirect (Online service)
  type of resource: text
  genre: bibliography
  genre: Electronic books.
  genre: Internet Resources.
  origin info:
    place:
      place term: enk
    date issued: 2017
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource : illustrations
  table of contents: Front Cover; Treating Life-Threatening Bleedings; Copyright Page; Contents; About the Author; Preface and Acknowledgments; 1. Classical Bleeding Disease (Hemophilia); 1.1 The History of Hemophilia; 1.2 The Treatment of Hemophilia; 1.2.1 Fraction 1-0; 1.2.2 The clinical use of Fraction 1-0; 1.2.3 Prophylaxis in severe hemophilia; References; 2. My Encounter With Hemophilia (1959-82); 2.1 The Coagulation Laboratory in Malmö; 2.2 Hemophilia Patients With Inhibitors, and a Method to Stop Bleeding in These Patients; 2.3 Plasma FVIIa for Hemophilia Patients.
  table of contents: 2.4 Treatment for the First Patients With FVIIa2.5 Potential Development of FVIIa to Be Used in Hemophilia; References; 3. The First Years at Novo Nordisk; 3.1 Recruitment by Novo Nordisk, 1983; 3.2 Hematology at Novo Industri During the 1980s; 3.2.1 The history of heparin and Novo Industri; 3.2.2 The development of modified heparins; 3.2.3 The development of LMWH at Novo Industri; 3.2.4 Substances to dissolve clots (thrombi); 3.2.5 The introduction of FVII at Novo Industri; References; 4. The Development of Recombinant FVIIa (rFVIIa) (1985-88); 4.1 Background and Start.
  table of contents: 4.2 Work on Recombinant FVIIa4.2.1 The organization of the hemostasis group; 4.2.2 Production challenges; 4.2.3 The development of necessary assays; 4.2.4 Characterization of the rFVIIa molecule; 4.2.5 Effects and side effects: preclinical animal studies; 4.3 Treatment of the First Patient With rFVIIa, 1988; References; 5. The Further Use and Development of rFVIIa (1989-96); 5.1 The Prompt Use of rFVIIa; 5.2 rFVIIa as a "Compassionate Use" Product in the United States; 5.3 Plans for the Clinical Development of rFVIIa; 5.4 The Merger of Novo and Nordisk Gentofte 1989 and Its Consequences.
  table of contents: 5.5 The Development and Licensing of rFVIIa 1990-965.6 The Development of Production Capacity and the US License; 5.7 Blood Product Advisory Committee, 1996; 5.8 Some Final Reflections; References; 6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors; 6.1 "Orphan Drug Act"; 6.2 Patent Rights (Intellectual Property); References; 7. Treatment With rFVIIa in Malmö (1996-99); 7.1 Part-Time Employment at the Coagulation Clinic in Malmö (1996-90); 7.2 The Third "Key Patient"; 7.3 What Did This Patient Teach Us?; References; 8. The Launching and Uses of rFVIIa.
  table of contents: 8.1 The Launching of rFVIIa (1996-2000)8.2 rFVIIa for Use in Areas Other Than Hemophilia; 8.2.1 rFVIIa and platelet dysfunctions; 8.2.2 rFVIIa and liver diseases; 8.2.3 rFVIIa and patients with a normal coagulation system; 8.2.4 rFVIIa and trauma; 8.2.5 rFVIIa and patients with cerebral hemorrhages; References; 9. Mechanism of Action and Dosage; 9.1 Mechanism of Action; 9.2 Dosage; References; 10. The Continued Development of rFVIIa During the 2000s; 10.1 rFVIIa-Potential Long-term Effect; 10.1.1 The distribution in the blood of injected rFVIIa.
  note: Ulla K.E. Hedner.
  note: Includes bibliographical references and index.
  subject:
    topic: Blood coagulation factors
  subject:
    topic: Blood coagulation factor VIII
  subject:
    topic: Blood coagulation disorders
    topic: Treatment
  subject:
    topic: Hemophilia
    topic: Treatment
  subject:
    topic: 1900s
  subject:
    topic: 2000s
  subject:
    topic: Factor VIIa
    topic: history
  subject:
    topic: Blood Coagulation Disorders
    topic: drug therapy
  subject:
    topic: Recombinant Proteins
    topic: therapeutic use
  subject:
    topic: Blood Coagulation Factors
  subject:
    topic: Factor VIII
  subject:
    topic: Sang
    topic: Coagulation
    topic: Facteurs
  subject:
    topic: Sang
    topic: Coagulation
    topic: Facteur VIII
  subject:
    topic: Sang
    topic: Troubles de la coagulation
    topic: Traitement
  subject:
    topic: Hémophilie
    topic: Traitement
  subject:
    topic: HEALTH & FITNESS
    topic: Diseases
    topic: General
  subject:
    topic: MEDICAL
    topic: Clinical Medicine
  subject:
    topic: MEDICAL
    topic: Diseases
  subject:
    topic: MEDICAL
    topic: Evidence-Based Medicine
  subject:
    topic: MEDICAL
    topic: Internal Medicine
  subject:
    topic: Blood coagulation disorders
    topic: Treatment
  subject:
    topic: Blood coagulation factor VIII
  subject:
    topic: Blood coagulation factors
  subject:
    topic: Hemophilia
    topic: Treatment
  classification: RM171.5
  classification: 616.1506
  classification: 2017 H-025
  classification: WH 11.1
  related item:
    title info:
      title: Treating life-threatening bleedings
    name:
      name part: Hedner, U. (Ulla).
    origin info:
      publisher: London : Academic Press, [2017]
    identifier: (OCoLC)974698989
  identifier: 9780128124406
  identifier: 0128124407
  identifier: 9780128124390
  identifier: 0128124393
  identifier: 2017946970
  identifier: 9780128124406 Ingram Content Group
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record content source: N$T
    record creation date: 170710
    record change date: 20260327152226.0
    record identifier: in00005762156
    language of cataloging:
      language term: eng